Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae.

× No keyword cloud information.

10 in total

Review 1. Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin.

Authors: Jennifer Shiu; Grace Ting; Tony Kl Kiang
Journal: Eur J Drug Metab Pharmacokinet Date: 2019-06 Impact factor: 2.441

2. In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors: Robert K Flamm; Paul R Rhomberg; Michael D Huband; David J Farrell
Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191

Review 3. Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection.

Authors: Vanessa R Anderson; Caroline M Perry
Journal: Drugs Date: 2008 Impact factor: 9.546

4. Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy.

Authors: Ayman M Noreddin; Walid F Elkhatib; Kenji M Cunnion; George G Zhanel
Journal: Drug Healthc Patient Saf Date: 2011-10-07

5. In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections.

Authors: S McCurdy; L Lawrence; M Quintas; L Woosley; R Flamm; C Tseng; S Cammarata
Journal: Antimicrob Agents Chemother Date: 2017-08-24 Impact factor: 5.191

6. In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014.

Authors: M A Pfaller; H S Sader; P R Rhomberg; R K Flamm
Journal: Antimicrob Agents Chemother Date: 2017-03-24 Impact factor: 5.191

Review 7. Delafloxacin: design, development and potential place in therapy.

Authors: Francisco Javier Candel; Marina Peñuelas
Journal: Drug Des Devel Ther Date: 2017-03-20 Impact factor: 4.162

8. Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone.

Authors: M A Pfaller; R K Flamm; S P McCurdy; C M Pillar; D Shortridge; R N Jones
Journal: J Clin Microbiol Date: 2018-07-26 Impact factor: 5.948

Review 9. Profile of a Novel Anionic Fluoroquinolone-Delafloxacin.

Authors: Paul M Tulkens; Françoise Van Bambeke; Stephen H Zinner
Journal: Clin Infect Dis Date: 2019-04-08 Impact factor: 9.079

Review 10. Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline.

Authors: Béla Kocsis; Dániel Gulyás; Dóra Szabó
Journal: Antibiotics (Basel) Date: 2021-12-08

10 in total